Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Oct 29;19:1019. doi: 10.1186/s12885-019-6138-7

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s). 2019

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

PMC Copyright notice

Fig. 1 — Clinicopathological findings of colitis in case 1: a Computed tomography of the abdomen on Day 95 after initiation of nivolumab showed an edematous lesion involving the rectosigmoid colon. b (a) Colonoscopy on Day 96 revealed an ulcerative lesion in the rectosigmoid colon. (b) Colonoscopy on Day 103 revealed that ulcerative lesion was improved but remained after corticosteroids administration. (c) (d) Immunohistochemical staining (CD8, CD4 and T-bet) of colon biopsy samples on Day 96 and Day 103. (e) (f) Immunohistochemical staining (CD8, CD4 and Foxp3) of colon biopsy samples on Day 96 and Day 103 showed increased infiltration of CD8⁺ and Foxp3⁺ cells after corticosteroids administration